Protagenic Therapeutics Inc (PTIX) Is A Buy According To Analysts

Protagenic Therapeutics Inc (NASDAQ:PTIX) has seen 0.57 million shares traded in the recent trading session. The company, currently valued at $4.74M, closed the recent trade at $0.70 per share which meant it gained $0.14 on the day or 24.29% during that session. The PTIX stock price is -167.14% off its 52-week high price of $1.87 and 35.71% above the 52-week low of $0.45. If we look at the company’s 10-day average daily trading volume, we find that it stood at 63440.0 shares traded. The 3-month trading volume is 174.08K shares.

Protagenic Therapeutics Inc (NASDAQ:PTIX) trade information

Sporting 24.29% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PTIX stock price touched $0.70 or saw a rise of 8.14%. Year-to-date, Protagenic Therapeutics Inc shares have moved -29.70%, while the 5-day performance has seen it change 33.79%. Over the past 30 days, the shares of Protagenic Therapeutics Inc (NASDAQ:PTIX) have changed 20.02%. Short interest in the company has seen 89119.0 shares shorted with days to cover at 1.33.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Protagenic Therapeutics Inc (PTIX) estimates and forecasts

The company’s shares have lost -27.50% over the past 6 months.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -2.91% over the past 5 years.

PTIX Dividends

Protagenic Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Protagenic Therapeutics Inc (NASDAQ:PTIX)’s Major holders

Insiders own 14.25% of the company shares, while shares held by institutions stand at 5.77% with a share float percentage of 6.73%. Investors are also buoyed by the number of investors in a company, with Protagenic Therapeutics Inc having a total of 11.0 institutions that hold shares in the company.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. As of Sep 30, 2024, the former fund manager holds about 0.47% shares in the company for having 32.0 shares of worth $20957.0 while later fund manager owns 17.06 shares of worth $11173.0 as of Oct 31, 2024, which makes it owner of about 0.25% of company’s outstanding stock.